[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n Mi25NyTTQnFIPYm8/wmCBzhLodJDcVxnvO5r5aE1Rc8zr4Clym1bfr5K9cuqUM0t\n cSKAPo9Rfu7RJNj3tp22jQ==\n\n', u'0000950137-04-007574.txt : 20040909\n', u'0000950137-04-007574.hdr.sgml : 20040909\n', u'20040909123843\nACCESSION NUMBER:\t\t0000950137-04-007574\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t3\nCONFORMED PERIOD OF REPORT:\t20040908\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20040909\nDATE AS OF CHANGE:\t\t20040909\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tAASTROM BIOSCIENCES INC\n\t\tCENTRAL INDEX KEY:\t\t\t0000887359\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tSERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]\n\t\tIRS NUMBER:\t\t\t\t943096597\n\t\tSTATE OF INCORPORATION:\t\t\tMI\n\t\tFISCAL YEAR END:\t\t\t0630\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t000-22025\n\t\tFILM NUMBER:\t\t041022199\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t24 FRANKL LLOYD WRIGHT DR\n\t\tSTREET 2:\t\tPO BOX 376\n\t\tCITY:\t\t\tANN ARBOR\n\t\tSTATE:\t\t\tMI\n\t\tZIP:\t\t\t48106\n\t\tBUSINESS PHONE:\t\t7349305555\n', u'\n', u'\n', u'8-K\n', u'1\n', u'a01737e8vk.htm\n', u'FORM 8-K\n', u'\n', u'Aastrom Biosciences, Inc.', u'\n', u' PAGEBREAK ', u'\n', u'Table of Contents', u'\n', u'\n', u'\n', u'\n', u'UNITED STATES SECURITIES AND EXCHANGE COMMISSION', u'\n', u'Washington, D.C. 20549', u'\n', u'\n', u'\n', u'Form\xa08-K', u'\n', u'CURRENT REPORT', u'\nPURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934', u'\n', u'Date of report (date of earliest event reported):', u'\n', u'September\xa08, 2004', u'\n', u'Aastrom Biosciences, Inc.', u'\n', u'(Exact name of registrant as specified in its charter)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Michigan', u'\n', u'\n', u'\xa0', u'\n', u'0-22025', u'\n', u'\n', u'\xa0', u'\n', u'94-3096597', u'\n', u'\n', u'\n', u'(State or other jurisdiction of', u'\nincorporation)\n', u'\n', u'\xa0', u'\n', u'(Commission File No.)\n', u'\n', u'\xa0', u'\n', u'(I.R.S. Employer Identification', u'\nNo.)', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'24 Frank Lloyd Wright Drive', u'\nP.O. Box 376', u'\nAnn Arbor, Michigan 48106', u'\n(Address of principal executive offices)\n\n\n\n', u'Registrant\x92s telephone number, including area code:', u'\n', u'(734)\xa0930-5555', u'\n', u'Check the appropriate box below if the Form 8-K filing is intended to\nsimultaneously satisfy the filing obligation of the registrant under any of the\nfollowing provisions:\n\n\n\n', u'\n', u'\n', u'\n', u'o', u'\n', u'\xa0', u'\n', u'Written communications pursuant to Rule\xa0425 under the Securities Act (17\nCFR 230.425)', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'o', u'\n', u'\xa0', u'\n', u'Soliciting material pursuant to Rule\xa014a-12 under the Exchange Act (17\nCFR 240.14a-12)', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'o', u'\n', u'\xa0', u'\n', u'Pre-commencement communications pursuant to Rule\xa014d-2(b) under the\nExchange Act (17 CFR 240.14d-2(b))', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'o', u'\n', u'\xa0', u'\n', u'Pre-commencement communications pursuant to Rule\xa013e-4(c) under the\nExchange Act (17 CFR 240.13e-4(c))', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\n', u' TOC ', u'\n', u'TABLE OF CONTENTS', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Item\xa02.02 Results of Operations and Financial Condition.', u'\n', u'Item\xa09.01 Financial Statements and Exhibits.', u'\n', u'SIGNATURES', u'\n', u'EXHIBIT 99.1', u'\n', u'\n', u'\n', u' /TOC ', u'\n', u'\n', u'Table of Contents', u'\n', u' link2 "Item&nbsp;2.02 Results of Operations and Financial Condition." ', u'\n', u'\n', u'Item\xa02.02 Results of Operations and Financial Condition.', u'\n', u'\xa0\xa0\xa0\xa0\xa0On September\xa08, 2004, we issued a press release announcing financial\nresults and operational achievements for our fourth fiscal quarter and fiscal\nyear ended June\xa030, 2004. A copy of the press release is attached hereto as\nExhibit\xa099.1.\n\n\n', u'\xa0\xa0\xa0\xa0\xa0Pursuant to General Instruction B.2 of Form 8-K, this report and the\nexhibit are not deemed to be \x93filed\x94 for purposes of Section\xa018 of the\nSecurities Exchange Act of 1934, nor shall this report and the exhibit be\nincorporated by reference into our filings under the Securities Act of 1933 or\nthe Securities Exchange Act of 1934, except as expressly set forth by specific\nreference in such future filing.\n\n', u' link2 "Item&nbsp;9.01 Financial Statements and Exhibits." ', u'\n', u'\n', u'Item\xa09.01 Financial Statements and Exhibits.', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(c)', u'\n', u'\xa0', u'\n', u'Exhibits.', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Exhibit No.', u'\n', u'\xa0', u'\n', u'Description', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'99.1\n', u'\n', u'\xa0', u'\n', u'Press Release dated September\xa08, 2004', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u' link1 "SIGNATURES" ', u'\n', u'\n', u'SIGNATURES', u'\n', u'\xa0\xa0\xa0\xa0\xa0Pursuant to the requirements of the Securities Exchange Act of 1934, the\nregistrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized.\n\n\n', u'Date: September\xa08, 2004\n\n\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'AASTROM BIOSCIENCES, INC.', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'By:\xa0\xa0', u'\n', u'/s/ Alan M. Wright\n\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Alan M. Wright\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Senior Vice President,\nAdministrative and\nFinancial Operations, CFO\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2\n', u'\n', u'\n', u'\n', u'\n', u'EX-99.1\n', u'2\n', u'a01737exv99w1.htm\n', u'EXHIBIT 99.1\n', u'\n', u'Aastrom Biosciences, Inc.', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0FOR IMMEDIATE RELEASE', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0CONTACTS:\n', u'\n', u'\xa0', u'\n', u'Kris M. Maly or\n', u'\n', u'\xa0', u'\n', u'Kevin McGrath', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Becky Anderson\n', u'\n', u'\xa0', u'\n', u'Cameron Associates', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Investor Relations Department\n', u'\n', u'\xa0', u'\n', u'Phone: (212)\xa0245-4577', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Aastrom Biosciences, Inc.', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Phone: (734)\xa0930-5777', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'AASTROM BIOSCIENCES, INC. REPORTS FOURTH QUARTER 2004', u'\nFINANCIAL RESULTS', u'\n', u'Ann Arbor, Michigan, September\xa08, 2004 \x97 ', u'Aastrom Biosciences, Inc. (NasdaqSC:\nASTM) today reported financial results for the fourth quarter and fiscal year\nended June\xa030, 2004. The Company also reported significant achievements during\nthe last quarter and fiscal year, both clinically and operationally. For the\nquarter ended June\xa030, 2004, these achievements included:\n\n\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Expanding U.S. Phase I/II clinical trial for bone fractures to\ninclude a second site. We added The University of Michigan Health\nSystem\x92s orthopedic trauma center for the trial of our bone generation\nTissue Repair Cell (TRC)\xa0adult stem cell product. We expect a third\nclinical site to be included in this trial for patients with severe\ntibial leg fractures', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Appointing James A. Cour President and Chief Operating Officer on\nJuly 6th, strengthening senior management\x92s operational expertise.\nPreviously Mr.\xa0Cour held executive level management positions with\nBaxter International, Windsor VanGelder Limited and Cytomedix', u'\n', u'\n', u'\n', u'\x93Aastrom achieved a significant number of milestones in fiscal year 2004, led\nby the expansion and advancement of our clinical trials for patient treatment\nand our product development pipeline,\x94 commented R. Douglas Armstrong, Ph.D.,\nChief Executive Officer and Chairman of Aastrom. \x93We are demonstrating\nmaterial progress toward our goal of generating a focused portfolio of adult\nstem cell-based products for the regenerative repair of damaged human tissues\nthat have substantial therapeutic and commercial potential. I believe fiscal\nyear 2005 is going to be an important year in our evolution from the research\nand development phase into the commercialization phase as we expand the\nclinical evaluation of our adult stem cell-based TRCs for tissue regeneration,\nand begin to report on the results.\x94\n\n\n\n', u'Other significant highlights during the 2004 fiscal year included the\nfollowing:\n\n\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Received the Company\x92s first TRC-related FDA approved\nInvestigational New Drug (IND)\xa0application for a multi-center clinical\ntrial for local bone repair, followed by the initiation of our lead\nclinical trial site in Chicago, IL', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Commenced European Union (EU)\xa0bone graft clinical studies with\nBG-Kliniken \x91Bergmannsheil\x92 Ruhr-University Hospital in Germany and the\nHospital General de l\x92Hospitalet in Barcelona, Spain. These studies\nutilize our proprietary bone-forming TRCs in combination with\ncommercial synthetic matrix products to treat non-union large bone\nfractures', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Issued a patent by the U.S. Patent and Trademark Office that covers\na method of bone marrow transplantation, often referred to as stem cell\ntransplants, using cells produced with our proprietary single-pass\nperfusion technology', u'\n', u'\n', u'\n', u'-more-\n\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'Aastrom-4', u'th', u' Q', u'\nSeptember\xa08, 2004', u'\nPage 2\n\n\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Awarded a Phase I SBIR grant by the NIH for the development of a\nbone marrow stem cell-based treatment of circulation ischemia caused by\nvascular diseases and diabetes', u'\n', u'\n', u'\n', u'Fourth Quarter and Twelve Months ended June\xa030, 2004 Results', u'\n', u'Total revenue for the quarter ended June\xa030, 2004, consisting of product sales\nand rentals in the EU and grants, was $0.2\xa0million, unchanged from the same\nperiod in fiscal year 2003. Total revenue for the twelve months ended June\xa030,\n2004 was $1.3\xa0million compared to $0.8\xa0million for the same period in fiscal\nyear 2003.\n\n\n\n', u'Net loss for the quarter ended June\xa030, 2004 was $2.7\xa0million, or $.03 per\nshare, compared to a net loss of $2.7\xa0million, or $.05 per share for the same\nperiod in fiscal year 2003. Net loss for the twelve months ended June\xa030,\n2004, was $10.5\xa0million, or $.14 per share, compared to $9.6\xa0million, or $.19\nper share for the same period in fiscal year 2003.\n\n\n\n', u'At June\xa030, 2004, the Company had $16.9\xa0million in cash, cash equivalents and\nmarketable securities as compared to $10.5\xa0million in cash, cash equivalents\nand marketable securities at June\xa030, 2003.\n\n\n\n', u'\x93Our financial condition continues to be strong. The Company\x92s cash position\nand our controlled level of expenditures allow us to advance our ongoing bone\ngrafting clinical trials, and move forward with the planned expansion of our\nclinical trials program,\x94 said Alan M. Wright, Senior Vice President\nAdministrative and Financial Operations and Chief Financial Officer of Aastrom.\n\n\n\n', u'Total costs and expenses for the quarter ended June\xa030, 2004 were $3.0\xa0million,\ncompared to $2.9\xa0million for the same period in fiscal year 2003. Total costs\nand expenses for the twelve months ended June\xa030, 2004 increased to $12.0\nmillion, compared to $10.6\xa0million for the same period in fiscal year 2003.\n\n\n\n', u'Research and development expenses for the quarter ended June\xa030, 2004 increased\nslightly to $1.8\xa0million, from $1.5\xa0million for the same period in fiscal year\n2003. Research and development expenses for the twelve months ended June\xa030,\n2004 increased to $6.3\xa0million, compared to $5.6\xa0million for the same period in\nfiscal year 2003. These increases reflect our continued research and product\ndevelopment activities in the area of tissue regeneration, including our\non-going and planned bone grafting clinical trials in the United States and the\nEU.\n\n\n\n', u'Selling, general and administrative expenses increased slightly to $1.2\xa0million\nfor the quarter ended June\xa030, 2004, compared to $1.1\xa0million for the same\nperiod in fiscal year 2003. Selling, general and administrative expenses\nincreased to $5.4\xa0million for the twelve months ended June\xa030, 2004, from $4.0\nmillion for the same period in fiscal year 2003. The increase in these\nexpenses resulted from continued expansion of business and clinical trial\nactivities in the EU, and additional capital raising expenses not related to\nspecific transactions. Selling, general and administrative expenses for fiscal\nyear ended June\xa030, 2004 also include a non-cash charge of $53,000 relating to\ncertain warrants issued in August\xa02003 for public and investor relations\nservices and a $372,000 non-cash charge related to an employee\nperformance-based stock option that vested in September\xa02003.\n\n\n\n', u'Dr.\xa0Armstrong concluded, \x93After serving with distinction for the past 6\xa0years\nwe regretfully report that on August\xa05, 2004, Mary Lincoln Campbell resigned\nfrom our Board and as audit committee chairperson, due to the requirements of\nher other business commitments. We thank Mary for her many contributions and\nfor her devotion to helping guide the Company through important issues over the\nyears.\x94\n\n\n', u'-more-\n\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'Aastrom-4', u'th', u' Q', u'\nSeptember\xa08, 2004', u'\nPage 3\n\n\n\n', u'Outlook for the Coming Year', u'\n', u'Aastrom entered fiscal year 2005 with sufficient funding to support planned\nclinical and operational goals and objectives, including:\n\n\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Continue the accrual of patients in our current FDA multi-center\nbone graft trial in the U.S., and add a third institution as a clinical\nsite', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Complete the first phase of clinical studies in the EU for bone\ngrafting repair of severe non-union fractures; pending positive\nresults, move toward commercialization', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Initiate and complete a jaw bone reconstruction clinical trial in\nthe EU for sinus lift procedures for dental implants', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Prepare for and initiate an EU clinical study utilizing TRCs to\nregenerate vascular tissue in patients with diabetic limb ischemia', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Pursue applicable opportunities for grants, to further define\npotential uses and applications for our proprietary technology and cell\nproducts', u'\n', u'\n', u'\n', u'Aastrom Conference Call Information', u'\n', u'R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, James A.\nCour, President and Chief Operating Officer, and Alan M. Wright, Senior Vice\nPresident Administrative & Financial Operations and Chief Financial Officer of\nAastrom Biosciences, Inc., will review and discuss the fourth quarter fiscal\nyear 2004 financial results and the Company\x92s recent progress and future goals\ntoday, September\xa08, 2004, at 11:00\xa0a.m. (EDT)\xa0when they will host a conference\ncall. Interested parties should call (785)\xa0832-1508, or toll-free (800)\n540-0559, fifteen minutes before the start of the call to register and identify\nthemselves as registrants of the \x91Aastrom Conference Call\x92. The call will be\nsimulcast on the web at\nhttp://phx.corporate-ir.net/playerlink.zhtml?c=85924&s=wm&e=938425, and the\nentire call will be archived for replay at the same site for 90\xa0days.\n\n\n\n', u'About Aastrom Biosciences, Inc.', u'\n', u'Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is developing proprietary stem\ncell-based products for the regenerative repair of damaged human tissues and\nother medical disorders. Aastrom\x92s strategic position in the tissue\nregeneration and cell therapy sectors is enabled by its proprietary Tissue\nRepair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the\nAastromReplicell\xae System, an industry-unique automated cell production platform\nused to produce cells for clinical use. Together TRCs and the AastromReplicell\nSystem provide a foundation that the Company is leveraging to produce multiple\nPrescription Cell Products (PCPs), the first of which is now in the clinical\nstage in the U.S. and EU.\n\n\n\n', u'TRCs are the core component of the PCPs Aastrom is developing for the bone\ngrafting, peripheral vascular disease and cartilage markets. The Company also\nmarkets the AastromReplicell System and disposable dendritic cell production\nkits to researchers and institutions developing vaccines to treat cancer and\ninfectious diseases, under its Cell Production Products line.\n\n\n\n', u'For more information, visit Aastrom\x92s website at www.aastrom.com.\n\n\n', u'-more-\n\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'Aastrom-4', u'th', u' Q', u'\nSeptember\xa08, 2004', u'\nPage 4\n\n\n\n', u'This document contains forward-looking statements, including without\nlimitation, statements concerning clinical trial plans and expectations,\nintended product development and commercialization objectives, the expected\nadequacy of capital resources to support planned activities, plans for the\ncurrent fiscal year, potential product applications, and potential advantages\nof the AastromReplicell System and related cell therapy products, which involve\ncertain risks and uncertainties. The forward-looking statements are also\nidentified through use of the words \x93expect,\x94 \x93planned,\x94 \x93potential,\x94\n\x93believe,\x94 and other words of similar meaning. Actual results may differ\nsignificantly from the expectations contained in the forward-looking\nstatements. Among the factors that may result in differences are the inherent\nuncertainties associated with clinical trial and product development\nactivities, regulatory approval requirements, the availability of resources and\nthe allocation of resources among different potential uses. ', u'These and other\nsignificant factors are discussed in greater detail in Aastrom\x92s Annual Report\non Form10-K and other filings with the Securities and Exchange Commission.', u'\n', u'\x97 Financial Table Follows \x97\n\n\n\n', u'-more-\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'AASTROM BIOSCIENCES, INC.', u'\n', u'CONSOLIDATED STATEMENT OF OPERATIONS DATA:', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Quarter ended June 30,', u'\n', u'\xa0', u'\n', u'Year ended June 30,', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\xa0', u'\n', u'2004', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(Unaudited)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'REVENUES:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Product sales and rentals', u'\n', u'\xa0', u'\n', u'$', u'\n', u'16,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'4,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'314,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'49,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Grants and other', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'159,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'206,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'530,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,253,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total revenues', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'175,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'210,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'844,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,302,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'COSTS AND EXPENSES:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cost of product sales and rentals', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'13,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'145,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'27,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cost of product sales and rentals \x96 provision\nfor obsolete and excess inventory', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'303,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'748,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'253,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Research and development', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,479,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,818,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,647,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,289,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Selling, general and administrative', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,148,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,190,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,017,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,390,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total costs and expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,943,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,013,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10,557,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,959,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'OTHER INCOME', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'30,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'56,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'134,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'169,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'NET LOSS', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(2,738,000', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(2,747,000', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(9,579,000', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(10,488,000', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'NET LOSS PER SHARE', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(Basic and Diluted)', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(.05', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(.03', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(.19', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(.14', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Weighted average number of common shares outstanding', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'58,945,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'80,713,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'50,984,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'73,703,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'CONSOLIDATED BALANCE SHEET DATA:', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'June 30, 2004', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'ASSETS:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash and investments ', u'\n', u'\xa0', u'\n', u'$', u'\n', u'16,926,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other current assets ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'906,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Property, net ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'334,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total assets ', u'\n', u'\xa0', u'\n', u'$', u'\n', u'18,166,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'LIABILITIES AND SHAREHOLDERS\x92 EQUITY:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current liabilities ', u'\n', u'\xa0', u'\n', u'$', u'\n', u'558,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Shareholders\x92 equity ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,608,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total liabilities and shareholders\x92 equity ', u'\n', u'\xa0', u'\n', u'$', u'\n', u'18,166,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'# # #\n\n\n\n\n', u'\xa0\n', u'\n', u'\n', u'\n', u'\n', u'GRAPHIC\n', u'3\n', u'a01737a0173700.gif\n', u'GRAPHIC\n', u'\nbegin 644 a01737a0173700.gif\nM1TE&.#EA-@(Z`//CX^KJZO\'Q\\?CX^/_[\\*"@I("`@/\\```#_\nM`/__````__\\`_P#______RP`````-@(Z```(_@#_"1Q(L*#!@P@3*EPX8>&_\nM(10H3("PSJ\'%BPCI8=S(L:/\'CR!#BAQ)LJ3)DRA3JES)LB5"=@HF.92DH&8$\nMEPO?-0J&`+&W$&:$FN^&3E!PTZC5JUBS:MW*M2O/\nM=0K2`\'&TT(&">!440!AJ=HC7MW#CRIU+M^Y\'>0J(`-G;*R%-"?]H*H`G]$%2\nMNX@3*U[,N+%)"6\'W`DF3\\.D!@35W+J0W3YYGC9L]?Q[H.9[A"/1$>QY(KYT\\\nM@9SCS3/(>73">0?BL:;\'.2-OWHZ#"Q].?#&\\O)+W;CAX0.U`?#4)9V1\'P6Q-\nM!0PH1#W(K@*#ZS6\'_K2)]QV\\^0(+W)EBO":\'-9=;L)GR__(["\nM`P8..%!!.P1),L%_`$:`3W$,-NC@@T%%T$!R0(SS#U,%I;7=/_,81@%"QV%G\nM7SSQ\'-"&3:`)]$Y-#T@"#XGPP*2`?>^\\8Q8$!]18XP$\'0*?``_(,8=YKS:G5\nMSHOQO\',B5;K](X\\D[BEP``5J#2%!!.4-P9N0#%@YQ\'RO02CFF&26:=&*15`X\nMCST6%,3+CP4M&69!S4F0XD`A`B90D9(', u'$I0C0F%2&U-?684;:"\'\'>3C6@2%\nMZ"A"-0%:J:ATTF>N0/*8M>"V"">LL%#S+*!4', u'Q&Q]D)5D)":*=0HI351:U">E=6[\\,LPQUP26&@D1UDO%-HSCUGOQ*/HSR^Z\nMQX"Z%NTZHT!I*5#!M0B!;!!T##1),+P6A?AKI4SC61.!"#WE@,Q@ARVV0PI0\nM0&%?1E!H@8SFM:V`Q04MRDX;$PQ1WL8$"UD3_@,2L-/S04X7!+74*)]E$3U/\nMN84UB%1W#>?8D$', u'08$3-/BZ-2VKD)"*\\\\JX`O$>]%2ND@', u'Z]&_3[\\.RW7V9:R0/QQC^4\nM9`[$4UPKY-X#&M5:=KMX4PBHRG.?[PED=@,IDLH40@\\A5:!P61-(B-)7D/6Y\nM[X(8\'$YSC"0\\P`H824BD"56I>!ZG4]1*"EZ/]PX#_0.!`WN,0I!P+\nM@NAK&?`RR,,>V@4"_JE*3IM', u'#\\=(QJV@*6?VL%\\::J(J6.D**EX,6`#/EY#O6Q\'JYH\\$(0KA6(.N@3P%7]7"8MRNLR\\\\66(=A)#40&;T.\'NWX8](B>`#K3.!:\\5@2\nM!.8D(PJBLB91+$B\'%/`U6)KSG"6I5002^8\\+4*@(_HG`$!Z@#C=T$"&2_O!/\nM!80D@?BXK0T:J0`$*\'(/>*C#,.2\nMVA#1"CA``M>2!SX>,`2!5N`>!I%\'!")0@38L$)TPC:E#3F2YO4`29_;+J?P0\nM8IO4""1)[/`;/%(T#XVLYA_T@$=ZV"&)`\\AC8#^]1U"=RJ&BPF:3XCR`)*8*\nM#Z(A]:FPD0?14J.NSOA)(V:5J5K7>C$.\\N4?\\=-I', u'(DF&*7S-GA`6DC#;`(0CGXH95>/#"7"4B2&]@PYFQ\nM]L^K]#B`NG@SV7P=`*H(*>VG/F4N7DBGL+`M_B/W(J"J-M&C%QK(K6YWRUL-\nM6%91*)SA`P8*NP5.)*($@L]0BE@W8XP)IR*]^][M?-;Q!\nMGD,(\\$()PKMN$20"O;,14NG8L5E)S&T[*/D/21W52=]!+VD&$^$$*H`>\nM\\4B1`@B$U81TAR`G8NJD)O`KVH\'%Y=8#ZL(@ZCL!V"K15AMOR/>`"&*M*=\nMU:2:HR)4_F-77C4QA0$*DTF9ES.O[;*DP38/"@3XTA%`J7FYZP8T\\#\nMI4\'S(T@Z]#-!((K@5]$M$M2N.]OPCK>\\YTWO>MO[WOC.M[[WS6_&O%M;_^ZWP!DH\nMCP-', u':;,.\\', u'Z', u'%9`VE\'3#BPE(\nM`C4\'GN>L[C\'0AJAT"!"(UCX?\\%*#D"UE_CZ?ZCC,@^8S?9GH])`_>,>W84G%`!K@C,K\\``!\nMP"9_!P$', u'%8!KR4/`\'-:\nM3@(:KW$GLP$/"V)]HD(W!2$)Y#4/YP4W`P%2A\\8Q[1`U7/', u'&]*!=*Z0D_H/2!NK0)\\*2>[RP#E/B4D-#=NAU#_CP0)"((QJ##\\NV\nM+CH1+?`@=YJA)?]W,$,0#X:70/G-(,&/X=.M@(_+P#L)B\nM\'_!@>P*A#J`1#VFX1%]7$*;&+G,#AVW7;"^D$?#P(>]P`*', u'W@*>E"$%Y($/)0`?4(&`^@&]OW#^M0\nM`?LB;-!%&$AA[ZV4"4W=CN!(U5Q_CI!\nM52WR@(!:Q8M', u'!\\:TST%D1_W@%+P`!@FPB$&H1GRT`X3,!O>B`]1,5FY)PD5`"CW`%+T\nM("QC]RN3E1L4,"LP)PEN00^\\P\'.$D1ME-Q`-%6=!4B*>LEXQ9&HYET#Y8U"_\nMP@NSXHU553U\'`@\'@2`\'U6!\'9!XN1"0\'L.)85@8#J=0^Y5U1[Z4@">9JHF9JJ\nMN9JLZ5!@+)#[=`W#M`&\\``\\ZD`MI!A[F>2&NM&>,W0=\nMZG@Z>\'(KZDDH3--/4\\(.5L*"_300NJ@B\'P*70=66%G-L!*8N?>-UE-0MUT$:\nM?U2/T\'D9&E-76Q', u'2M(GO`"78W`]$.7`-Z&,AUN3@KDF`QE$1K[[!X-P&/Z"5M/3(K\nM["`UP--F8^$O4*:_A\nM4K(S*\\KZ0KH1D3W)"T45`508KN(ZKN1:KN9ZKDTX0J1!+?.@:RRX5?\'2BS_E\nM4NPP&ZV!DG]S#QNR#BC)I,V&K\'6X$`?93#$R&X*F=/&"YKZC*!R0#399R7;3&&R_E1-\nMT@Z2X$T(0;&P22"\\H&ERB$+OD(R.HHI(Q8N$QU2]LZJ.$B,QZY\']*E5NUV?X\nMD(PA=S!/V@[Z^@ZP-W)PLT`/A7>L88,7*PE;%K,.Q@[/^#1\'VTSZ)[\'_QXL;\nM=WLQ1;,D`6Q!NK9L.[2Q4', u'A!0.1"KRA":J[BF\nM^Q-#Z7*QTGIN`C!(U8VEQ`[DU2(9T7*TX2=0RY`45KA0A92[@33', u'%+`@#R`!\\Q"&S?0\\\nM;J%V;;`@RR41%0D89EEAZS!1@=$WS>F!R:DZ[ZDH3Y)JG4%2\\O``;3!1YH5W\nMS"6\\ODN1^)"I@Y"6@QAO!/(&\\6\'@N[R""!6&)6/>D"Y)K\nM0DHI1^=Z,LJD9DI>Q^:?ZH>4?IBI44%G:^&\'[U1.L4AF^$KS$+8&\\!T!%OU3AR&-R.\nM"?10N;*&R0)=^$"YW1B4A!&C5!H5Y?2#58&G5FIE\\Z`9U6B102(0:[&_/!Q#\nM#E!YOEO`04IVLS&CZ-L1.DNS0!#,Q(9\\$M8*8OBR-!\\TLD*J`I++$Z=F9*1=4T=G^4?]&WCFZX1%$A+-7S0H2Q#A8S&Y`*I,PJH\\(9\nM.CGL=TC%"X"1/Q4[G;CZ0C49+;\'Z;!H:GHXR7EYYR,@L$KDFH._@G:_(GNWJ\nM4K]BH)0KE>W:L1(:/>/QQ/,PP.^PB.U`JAX95%$1;>K%&[^RM%`\\=NQ)O^7+\nM9V],,/NIJ?48I)SQ1*2ZGXJR=P6,#P32L2C%5&\'\\?T\'5!I["C3$\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']